A Comparative Case for Shifting U.S. Generic Drug Policies to ...

of prescription drugs, the need for affordable medications is essential to the welfare of Americans. This is the role generic drugs play in the ...

I Want a New (Generic) Drug: A Comparative Case for Shifting U.S. ...

Enacted in 1984, Hatch-Waxman was intended to increase generic drug availability and make critical healthcare more affordable for Americans.

Influencers of Generic Drug Utilization: A Systematic Review - PMC

With an increase in prescription drug spending and rising drug costs there is a need to encourage the use of generic prescription drugs. However, maximizing ...

GENERIC DRUGS IN THE UNITED STATES: POLICIES TO ...

In many cases, however, in a strategy called “product-hopping,” the brand-name manufacturer precludes automatic switching of its drug for a generic version by ...

Repositioning Generic Drugs: Empirical Findings and Policy ...

Repositioning a generic drug is likely to be cheaper than developing a new compound. However, it is still likely to cost at least US$100 million ...

Comparison of pharmaceutical policies to stimulate use of generics ...

Swedish has introduced a number of policy changes and seems to have succeeded to achieve cost-containment of pharmaceutical expenditure whereas the Japanese ...

Repositioning Generics: The Comparative Value of Liability in FDA's ...

On one hand, generics are a product of basic free-market economic reasoning. Congress enacted the Drug Price Competition and Patent Term ...

Generic Drugs in the United States: Policies to Address Pricing and ...

We describe the strategies used by brand-name manufacturers to undermine generic competition and the reasons underlying the price increases of ...

State Laws and Generic Substitution in the Year After New Generic ...

In a cohort of patients starting one of 34 drugs in the year after generic competition began, we found that those in states requiring ...

Continuing trends in U.S. brand-name and generic drug competition

Generic unit sales during this period are made by a single or just a few manufacturers (the one or few first-filing generic drug manufacturers, and possibly an ...

Collusion in the US generic drug industry - ScienceDirect.com

We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data for the period 2011–2018 and a difference-in-differences ...

Differences in rates of switchbacks after switching from branded to ...

Results A total of 94 909 patients switched from branded to authorized generic drug products and 116 017 patients switched from branded to ...

Strategies that delay or prevent the timely availability of affordable ...

As we discuss in this article, brand-name drug companies have engaged in strategies that have delayed or prevented the availability of generic drugs, thereby ...

Examining Two Approaches to U.S. Drug Pricing: International ...

Evidence has shown that ERP is most effective when applied to pharmaceuticals without generic or therapeutic competition. 5. The comparison of prices of ...

Government regulated or negotiated drug prices: Key design ...

That means not only that U.S. consumers pay a lot, but also that reducing U.S. drug prices would lower manufacturer revenue and return on ...

Assessment of Variation in State Regulation of Generic Drug and ...

... policies on substitution of generic drugs for brand-name products throughout the US ... drug manufacturer not linked to seizures: a case ...

Prescription Drug Spending: Why Is the U.S. an Outlier?

Findings and Conclusions: Various factors contribute to high per capita drug spending in the U.S. While drug utilization appears to be similar ...

Comparing Generic Drug Markets in Europe and the United States

Barriers to Reforming Generic Drug Policies: A. Case Study From the United States ... drugs is price inelastic (ie, change in the price of a generic does not.

Comparing Generic Drug Markets in Europe and the United States ...

Policy Points: · Our study indicates that there are opportunities for cost savings in generic drug markets in Europe and the United States.

Policy Options to Reduce Prescription Drug Costs | Stanford Medicine

A shift from the current PBM model to a market competition model would be transformative in terms of drug policy in the US. By forcing manufacturers into a ...